Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
about
Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implicationsThe pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomicsClopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Discovery of novel GPVI receptor antagonists by structure-based repurposingPrasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study.Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.Construction of a drug safety assurance information system based on clinical genotyping.Radical cascade reaction of alkynes with N-fluoroarylsulfonimides and alcohols.Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.The 2012 ACCF/AHA Focused Update of the Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Guideline: a critical appraisalRole of cytochrome P450 genotype in the steps toward personalized drug therapy.Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelorClopidogrel variability: role of plasma protein binding alterationsPharmacogenetics and cardiovascular disease--implications for personalized medicineP2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.Influence of Cyp2c19*2 Gene Variant on Therapeutic Response During Clopidogrel Treatment in Patients with Carotid Artery Stenosis.Genetic causes of clopidogrel nonresponsiveness: which ones really count?Factors associated with clopidogrel nonresponsiveness.Clopidogrel in acute coronary syndrome: implications of recent study findings.Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.Pharmacogenetics guided anticoagulation.Thienopyridines in Acute Coronary Syndrome.Prasugrel resistance: fact or fiction.Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?Clopidogrel pharmacogenetics: metabolism and drug interactions.The pharmacogenetics of antiplatelet agents: towards personalized therapy?The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant?TRITON and beyond: new insights into the profile of prasugrel.Pharmacokinetic basis of the antiplatelet action of prasugrel.2011 ACCF/AHA focused update of the guidelines for the management of patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 Guideline): highlights for the clinician.A comprehensive comparative review of adenosine diphosphate receptor antagonists.Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus.
P2860
Q26771106-90C4EE94-673A-4898-B7B1-7E5FA18468AFQ26801867-CDC71550-381C-4825-890B-9548FF6EB65EQ26822796-7FD5B5FC-7EF0-46C8-B516-6FE3A440E064Q26823542-C986D22F-82F3-440C-AFB3-DCB15E955AE2Q28540147-6E14C96C-8122-49B4-AABE-CBFDBBE2DE3FQ33584173-C5648EB4-06E4-42BC-B548-3E6FD42CBF9CQ33622182-9C6130EB-01B0-4060-959F-E3D64634C172Q33704998-D11AB018-E92F-4C99-9395-5839D452B766Q33902628-D1805DA1-791E-4CE0-8523-38ED916DB9C0Q33963651-0A319EA1-9134-4F36-BD71-D4328FFD654CQ34624862-DB1C88B0-13D3-40EC-A7FE-285E2518B93DQ34981428-60E2748C-0ACC-4323-BB21-B57893016B99Q35529770-153F4C23-E3E9-462C-8BAC-26C269DBDBADQ35574813-0E23226D-C014-4DE7-A082-3B7D997AAD1CQ35640465-CC04FC80-ADD4-4B17-98E9-B526418FD5DBQ36367018-CE06E67F-26DE-4B0B-8FEC-71E659206429Q36441521-86564F14-7BFE-4685-8A30-76A7DF5EB751Q36807413-0A4045E6-8783-4020-BDEC-B41B9099AA4AQ36948114-91AC62AD-5F67-4D85-A3E3-7CECF7F00ED2Q36974672-9AEC467E-44AC-434E-83EA-9CC116AA5EA2Q37562606-A6713781-96C9-47E4-A334-0CFACDB30C34Q37629641-B05793C4-F09D-413E-81F6-88566E889763Q37694929-EC729249-F78A-4716-B990-9BA293AD3240Q37697779-7786CC6F-50D7-44A5-B1DB-15FC2403B842Q37709405-FEAD3A60-DBB2-4F73-85C0-CF9610B581EEQ37786639-83F1A1EF-178F-4986-A69A-DDB2FEDAF974Q37799470-2D47572B-016B-4011-B825-D92284CBCDE5Q37808224-92B23253-498F-4EDF-B0D8-670510160AB8Q37838124-15EBD3FC-1420-4BC3-A762-1A424FF2B844Q37905028-76649823-11AB-4104-B617-AC0E11779830Q37907902-49245D51-9E01-4672-8591-33BC146553E3Q37912178-988A4854-A1A7-4480-8D78-B510A8CFCD2BQ37913976-C87266FF-F04D-478F-835F-4190664F6A04Q37923969-7D07BD64-D212-475D-B809-B8FBE72ED510Q37924323-E160BF09-B3B7-4445-A0E1-42E3D33B8519Q37925009-76D2109F-4E24-4354-85A9-0A2B42A76CA2Q37927151-022E4D64-1A51-49A9-BEF2-E8B3CB99F534Q37965481-B12DCD2C-90D6-46C7-A9CA-103B3F543335Q37973114-4D133091-29DE-4A66-94EC-465B4778A3A0Q37997963-0EE5EA16-75FC-4807-ADEB-441D3375B350
P2860
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Genetic variation of CYP2C19 a ...... with coronary artery disease.
@en
Genetic variation of CYP2C19 a ...... with coronary artery disease.
@nl
type
label
Genetic variation of CYP2C19 a ...... with coronary artery disease.
@en
Genetic variation of CYP2C19 a ...... with coronary artery disease.
@nl
prefLabel
Genetic variation of CYP2C19 a ...... with coronary artery disease.
@en
Genetic variation of CYP2C19 a ...... with coronary artery disease.
@nl
P2093
P2860
P921
P356
P1476
Genetic variation of CYP2C19 a ...... with coronary artery disease.
@en
P2093
Christoph Varenhorst
David Erlinge
John T Brandt
Joseph Walker
Kenneth J Winters
Michael Man
Oscar O Braun
Sandra L Close
Stefan James
P2860
P304
P356
10.1093/EURHEARTJ/EHP157
P577
2009-05-09T00:00:00Z